We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters' Q3 earnings rose 16% year over year to $3.40 per share, topping estimates.
Quarterly sales climbed 8% to $800 million, driven by strength across segments and markets.
Waters raised 2025 guidance, now expecting up to 7.3% cc sales growth and higher earnings.
Waters Corporation (WAT - Free Report) reported third-quarter 2025 non-GAAP earnings of $3.40 per share, beating the Zacks Consensus Estimate by 5.92% and increasing 16% year over year.
Net sales of $800 million topped the Zacks Consensus Estimate by 2.59%. The figure increased by 8% both on a reported basis and on a constant currency (cc) basis year over year.
Waters’ Q3 Top Line in Detail
WAT operates under two organized segments: Waters and TA. The Waters segment generated sales worth $713.4 million, up 9% both on a reported and cc basis, year over year. Sales in the TA segment were $86.5 million, reflecting year-over-year growth of 2% both on a reported and cc basis.
Products & Services: The division comprises three segments: Instruments, Services, and Chemistry. Instruments sales were $341.5 million, increased 6% on a reported and cc basis, year over year. Services sales were $299.9 million, which increased 8% year over year on a reported basis and 7% at cc. Chemistry sales were $158.5 million, which grew 14% on a reported basis and 13% at cc, year over year. The Services and Chemistry segments jointly generated recurring revenues of $458.4 million, up 10% on a reported basis and 9% at cc, year over year.
Waters Corporation Price, Consensus and EPS Surprise
Waters serves three end markets: Pharmaceutical, Industrial, and Governmental & Academic. The Pharmaceutical market generated sales of $479.8 million, which increased 12% on a year-over-year basis, reportedly and 11% at cc. Industrial sales were $235.7 million, up 3% reportedly and 4% at cc, on a year-over-year basis. Government & Academic sales increased 2% reportedly and 1% at cc to $84.4 million.
Waters’ operating regions include Asia, the Americas and Europe. Asia generated sales of $269.7 million, up 7% and 13% on a reported and cc basis, respectively. Americas sales were $292.8 million, which increased 5% in both reported and cc terms. Europe generated sales of $237.4 million, which increased 13% reportedly and 5% at cc.
WAT’s Q3 Operating Details
In the third quarter of 2025, non-GAAP selling and administrative expenses were $179.7 million, up 8.3% year over year. As a percentage of net sales, the figure was flat on a year-over-year basis.
Research and development expenses of $49.9 million increased 11.7% year over year. As a percentage of net sales, the figure increased 20 bps year over year.
The adjusted operating margin was 30.3%, which contracted 50 bps year over year.
Waters Balance Sheet & Cash Flow
As of Sept. 27, 2025, cash and cash equivalents were $459.1 million, up from $367.2 million as of June 28.
Waters generated cash from operations of $187.3 million in the reported quarter. The company reported a free cash flow of $159.6 million.
WAT Raises 2025 Guidance
Waters raises 2025 cc sales growth guidance between 6.7% and 7.3%. Sales growth on a reported basis is expected in the 6.5%-7.1% range.
Waters is raising 2025 non-GAAP earnings in the $13.05 to $13.15 per share range. This reflects year-over-year growth of approximately more than 10% to more than 11% and more than 11% to more than 12% on a cc basis.
For the fourth quarter of 2025, Waters expects cc sales growth between 5% and 7%. Sales growth on a reported basis is expected in the 5.2%-7.2% range.
Waters expects non-GAAP earnings in the $4.45 to $4.55 per share range. This reflects year-over-year growth of approximately more than 9% to more than 11%.
Zacks Rank & Upcoming Earnings to Consider
Currently, Waters carries a Zacks Rank #3 (Hold).
ACADIA Pharmaceuticals (ACAD - Free Report) , ANI Pharmaceuticals (ANIP - Free Report) and Alcon (ALC - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector.
ANI Pharmaceuticals shares have returned 71% year to date. ANI Pharmaceuticals is scheduled to release third-quarter 2025 results on Nov. 7. ANI Pharmaceuticals has a Zacks Rank #2.
Alcon shares have dropped 12.6% year to date. Alcon is set to report its third-quarter 2025 results on Nov. 12. Alcon currently has a Zacks Rank #2.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y
Key Takeaways
Waters Corporation (WAT - Free Report) reported third-quarter 2025 non-GAAP earnings of $3.40 per share, beating the Zacks Consensus Estimate by 5.92% and increasing 16% year over year.
Net sales of $800 million topped the Zacks Consensus Estimate by 2.59%. The figure increased by 8% both on a reported basis and on a constant currency (cc) basis year over year.
Waters’ Q3 Top Line in Detail
WAT operates under two organized segments: Waters and TA. The Waters segment generated sales worth $713.4 million, up 9% both on a reported and cc basis, year over year. Sales in the TA segment were $86.5 million, reflecting year-over-year growth of 2% both on a reported and cc basis.
Products & Services: The division comprises three segments: Instruments, Services, and Chemistry. Instruments sales were $341.5 million, increased 6% on a reported and cc basis, year over year. Services sales were $299.9 million, which increased 8% year over year on a reported basis and 7% at cc. Chemistry sales were $158.5 million, which grew 14% on a reported basis and 13% at cc, year over year. The Services and Chemistry segments jointly generated recurring revenues of $458.4 million, up 10% on a reported basis and 9% at cc, year over year.
Waters Corporation Price, Consensus and EPS Surprise
Waters Corporation price-consensus-eps-surprise-chart | Waters Corporation Quote
Waters serves three end markets: Pharmaceutical, Industrial, and Governmental & Academic. The Pharmaceutical market generated sales of $479.8 million, which increased 12% on a year-over-year basis, reportedly and 11% at cc. Industrial sales were $235.7 million, up 3% reportedly and 4% at cc, on a year-over-year basis. Government & Academic sales increased 2% reportedly and 1% at cc to $84.4 million.
Waters’ operating regions include Asia, the Americas and Europe. Asia generated sales of $269.7 million, up 7% and 13% on a reported and cc basis, respectively. Americas sales were $292.8 million, which increased 5% in both reported and cc terms. Europe generated sales of $237.4 million, which increased 13% reportedly and 5% at cc.
WAT’s Q3 Operating Details
In the third quarter of 2025, non-GAAP selling and administrative expenses were $179.7 million, up 8.3% year over year. As a percentage of net sales, the figure was flat on a year-over-year basis.
Research and development expenses of $49.9 million increased 11.7% year over year. As a percentage of net sales, the figure increased 20 bps year over year.
The adjusted operating margin was 30.3%, which contracted 50 bps year over year.
Waters Balance Sheet & Cash Flow
As of Sept. 27, 2025, cash and cash equivalents were $459.1 million, up from $367.2 million as of June 28.
Waters generated cash from operations of $187.3 million in the reported quarter. The company reported a free cash flow of $159.6 million.
WAT Raises 2025 Guidance
Waters raises 2025 cc sales growth guidance between 6.7% and 7.3%. Sales growth on a reported basis is expected in the 6.5%-7.1% range.
Waters is raising 2025 non-GAAP earnings in the $13.05 to $13.15 per share range. This reflects
year-over-year growth of approximately more than 10% to more than 11% and more than 11% to more than 12% on a cc basis.
For the fourth quarter of 2025, Waters expects cc sales growth between 5% and 7%. Sales growth on a reported basis is expected in the 5.2%-7.2% range.
Waters expects non-GAAP earnings in the $4.45 to $4.55 per share range. This reflects year-over-year growth of approximately more than 9% to more than 11%.
Zacks Rank & Upcoming Earnings to Consider
Currently, Waters carries a Zacks Rank #3 (Hold).
ACADIA Pharmaceuticals (ACAD - Free Report) , ANI Pharmaceuticals (ANIP - Free Report) and Alcon (ALC - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector.
ACADIA Pharmaceuticals shares have appreciated 19.1% year to date. This Zacks Rank #2 (Buy) company is scheduled to release third-quarter 2025 results on Nov. 5. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ANI Pharmaceuticals shares have returned 71% year to date. ANI Pharmaceuticals is scheduled to release third-quarter 2025 results on Nov. 7. ANI Pharmaceuticals has a Zacks Rank #2.
Alcon shares have dropped 12.6% year to date. Alcon is set to report its third-quarter 2025 results on Nov. 12. Alcon currently has a Zacks Rank #2.